In order to further investigate the immunological profile of the primary tumors in both the 4T1 + RAW264.7 and 4T1 inoculation group, immunohistochemistry for CD45, CD163, Ly6G and CD8a was performed on primary tumor sections at pre- (1 and 3 w p.i.)and metastatic (5 w p.i.)time points (Fig. 6). The gene discussed is CD163; the disease is neoplasm.